LBA4 Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol

G. Attard,Louise Brown,Noel W. Clarke,L. Murphy,William Cross,Robert Jones,Silke Gillessen,J.M. Russell,Adrian Cook,J. Bowen,Anna Lydon,Ian Pedley,O. Parikh,Simon Chowdhury,Zafar Malik,David Matheson,Chris Parker,Matthew R. Sydes,Mona Parmar,N.D. James

LBA4 Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol

2021

This is an accepted manuscript of an abstract published by Elsevier in Annals of Oncology on 01/09/2021, available online: https://doi.org/10.1016/j.annonc.2021.08.2098 The accepted version of the publication may differ from the final published version.

Keywords:

non metastatic
Prostate cancer
Abiraterone acetate
Enzalutamide
Oncology
Coronavirus disease 2019
Androgen deprivation therapy
Prednisolone
Internal medicine
Medicine
2019 20 coronavirus outbreak

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations